Grufity logoGrufity logo

CPRX

17.27USD+0.64(+3.85%)Market Closed

Catalyst Pharmaceuticals Inc

Market Summary

USD17.27+0.64Market Closed
3.85%

CPRX Alerts

CPRX Stock Price

RSI Chart

Valuation

Market Cap

1.5B

Price/Earnings

26.77

Price/Sales

8.56

Price/Cashflow

19.31

MarketCap/EBT

20.1

Price/Sales

Profitability

EBT Margin

42.58%

Return on Equity

22.6%

Return on Assets

20.39%

Fundamentals

Revenue

Revenue (TTM)

191.8M

Revenue Y/Y

59.21%

Revenue Q/Q

7.78%

Earnings

Earnings (TTM)

66.9M

Earnings Y/Y

120.23%

Earnings Q/Q

5.22%

Price Action

52 Week Range

5.2418.39
(Low)(High)

Last 7 days

1.8%

Last 30 days

27.6%

Last 90 days

25.6%

Trailing 12 Months

144.6%

Financial Health

Current Ratio

10.79

Investor Care

Shares Dilution (1Y)

0.92%

Diluted EPS (TTM)

0.61

Peers (Alternatives to Catalyst Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Catalyst Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue12.5%192170154141134
Operating Expenses14.1%110969184
  S&GA Expenses3.7%5755535050
  R&D Expenses22.7%2117171716
Earnings Before Taxes16.4%8573605349
Net Income22.8%6754453942
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets24.6%333267247238223
  Current Assets13.9%276243221210193
    Cash Equivalents21.4%256211178171155
  Inventory-9.1%78887
  Net PPE-3.8%11111
Liabilities140.6%6326273125
  Current Liabilities98.7%4522232721
Shareholder's Equity12.0%270241220207199
  Retained Earnings1384.5%242-15.62-26.31-32.54
  Additional Paid-In Capital2.5%246239236233231
Accumulated Depreciation10.4%00000
Shares Outstanding1.3%104103103103103
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations25.9%9576656054
  Share Based Compensation7.9%77666
Cashflow From Investing-58.7%-0.35-0.22-11.02-10.98
Cashflow From Financing66.3%-3.08-9.17-9.88-8.14-5.59
  Buy Backs-33.7%1015141212

Risks

What is the probability of a big loss on CPRX?

90.8%


Probability that Catalyst Pharmaceuticals stock will be more than 20% underwater in next one year

68.5%


Probability that Catalyst Pharmaceuticals stock will be more than 30% underwater in next one year.

67.3%


Probability that Catalyst Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CPRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalyst Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on CPRX

43.4%


10-Year Cumulative Returns

31.6%


7-Year Cumulative Returns

31.5%


5-Year Cumulative Returns

55.9%


3-Year Cumulative Returns

What are the long-term rolling returns for CPRX?

FIve years rolling returns for Catalyst Pharmaceuticals.

Which funds bought or sold CPRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
REDUCED
-47.56
114,000
907,000
0.90%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
383,000
383,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.38
688,000
1,563,000
-%
2022-11-18
Cladis Investment Advisory, LLC
UNCHANGED
-
58,000
128,000
0.16%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-4,000
-
-%
2022-11-16
GLENMEDE TRUST CO NA
REDUCED
-2.27
97,000
219,000
-%
2022-11-15
JACOBS LEVY EQUITY MANAGEMENT, INC
REDUCED
-88.27
-5,324,000
1,455,000
0.01%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
SOLD OFF
-100
-204,000
-
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
443,000
443,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
814.87
3,402,190
3,618,280
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying CPRX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CPRX

Catalyst Pharmaceuticals News

Investor's Business Daily

Stock Market Pares Losses After Selling Off On Jobs Data; This IBD Index Holds Up.2 days ago

Yahoo Finance

Investor's Business Daily

CPRX Fair Value

Recent SEC filings of Catalyst Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading

Latest Insider Trading transactions for CPRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-23
Miller Steve
SOLD
-346,740
17.337
-20,000
Chief Operating Officer
2022-11-23
COELHO PHILIP H
SOLD
-174,483
17.45
-9,999
-
2022-11-22
COELHO PHILIP H
SOLD
-346,097
17.304
-20,001
-
2022-11-22
GRANDE ALICIA
SOLD
-1,983,240
16.527
-120,000
VP, Treasurer and CFO
2022-11-21
MCENANY PATRICK J
SOLD
-2,299,800
15.332
-150,000
President and CEO
2022-11-21
MCENANY PATRICK J
ACQUIRED
336,000
2.24
150,000
President and CEO
2022-11-21
Miller Steve
SOLD
-1,222,080
15.276
-80,000
Chief Operating Officer
2022-11-21
COELHO PHILIP H
SOLD
-1,066,170
15.231
-70,000
-
2022-11-18
MCENANY PATRICK J
SOLD
-5,467,700
15.622
-350,000
President and CEO
2022-11-18
MCENANY PATRICK J
ACQUIRED
784,000
2.24
350,000
President and CEO

1–10 of 50

Patrick J. McEnany
80
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 57,244$ 35,954$ 153,446$ 102,524
Operating costs and expenses:    
Cost of sales9,6655,31023,19814,536
Research and development8,3104,48715,69611,944
Selling, general and administrative14,16712,15343,51536,401
Total operating costs and expenses32,14221,95082,40962,881
Operating income25,10214,00471,03739,643
Other income (expense), net90568674211
Net income before income taxes26,00714,07271,71139,854
Income tax provision3,2593,74314,1039,681
Net income$ 22,748$ 10,329$ 57,608$ 30,173
Net income per share:    
Basic$ 0.22$ 0.1$ 0.56$ 0.29
Diluted$ 0.2$ 0.1$ 0.52$ 0.28
Weighted average shares outstanding:    
Basic103,318,572103,196,550102,967,280103,470,762
Diluted111,986,025107,843,196110,352,214107,476,175
Net income$ 22,748$ 10,329$ 57,608$ 30,173
Other comprehensive income (Note 4):    
Unrealized gain (loss) on available-for-sale securities, net of tax of ($52), $0, ($59) and $0, respectively162(26)180(94)
Comprehensive income22,91010,30357,78830,079
Product revenue, net [Member]    
Revenues:    
Total revenues57,17335,890153,25599,731
License and other revenue [Member]    
Revenues:    
Total revenues$ 71$ 64$ 191$ 2,793

CPRX Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 256,065$ 171,445
Short-term investments019,821
Accounts receivable, net9,3376,619
Inventory7,1327,870
Prepaid expenses and other current assets3,7764,351
Total current assets276,310210,106
Operating lease right-of-use asset2,8333,017
Property and equipment, net882959
License and acquired intangibles, net33,0510
Deferred tax assets, net20,02923,697
Deposits99
Total assets333,114237,788
Current Liabilities:  
Accounts payable2,5292,768
Accrued expenses and other liabilities42,15224,295
Total current liabilities44,68127,063
Operating lease liability, net of current portion3,6433,894
Other non-current liabilities14,7490
Total liabilities63,07330,957
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.001 par value, 200,000,000 shares authorized; 104,064,683 shares and 102,992,913 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively104103
Additional paid-in capital245,514233,186
Retained earnings (accumulated deficit)24,391(26,310)
Accumulated other comprehensive income (loss) (Note 4)32(148)
Total stockholders' equity270,041206,831
Total liabilities and stockholders' equity$ 333,114$ 237,788